Addex Therapeutics Ltd (NASDAQ:ADXN) Expected to Post FY2024 Earnings of ($0.36) Per Share

Addex Therapeutics Ltd (NASDAQ:ADXN) – Equities researchers at HC Wainwright lowered their FY2024 earnings estimates for Addex Therapeutics in a report issued on Wednesday, August 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.36) for the year, down from their prior forecast of ($0.34). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Addex Therapeutics’ current full-year earnings is ($11.80) per share. HC Wainwright also issued estimates for Addex Therapeutics’ FY2025 earnings at ($0.36) EPS.

Addex Therapeutics Stock Up 6.2 %

Shares of ADXN stock opened at $10.86 on Friday. The stock has a 50-day simple moving average of $8.21 and a 200 day simple moving average of $10.60. The stock has a market capitalization of $11.51 million, a P/E ratio of -0.63 and a beta of 1.77. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The firm had revenue of $0.27 million for the quarter.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.